Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A | P35498 | 2/20 | 0.42 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.42 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 6/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | HTR1A | P08908 | 2/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21352710 | 0.81 | SCN1A (0.43) | SCN1ASCN2ASCN3ACHRM5CHRM1 | |
| SCHEMBL12096236 | 0.80 | SCN1A (0.39) | SCN1ASCN2ASCN3ACHRM5CHRM1 | |
| SCHEMBL5944501 | 0.78 | SCN1A (0.45) | SCN1ASCN2ASCN3ACHRM5CHRM1 | |
| Hydrochloric Acid SCHEMBL22409396 | 0.76 | SCN1A (0.43) | SCN1ASCN2ASCN3ACHRM5CHRM1 | |
| Hydrochloric Acid SCHEMBL28431629 | 0.76 | SCN1A (0.43) | SCN1ASCN2ASCN3ACHRM5CHRM1 | |
| SCHEMBL5056258 | 0.75 | SCN1A (0.39) | SCN1ASCN2ASCN3ACHRM5CHRM1 | |
| SCHEMBL3696758 | 0.74 | SCN1A (0.42) | SCN1ASCN2ASCN3ACHRM5CHRM1 | |
| SCHEMBL28761585 | 0.74 | SCN1A (0.42) | SCN1ASCN2ASCN3ACHRM5CHRM1 | |
| SCHEMBL3686620 | 0.74 | SCN1A (0.42) | SCN1ASCN2ASCN3ACHRM5CHRM1 | |
| Fluoromethane SCHEMBL27938158 | 0.73 | SCN1A (0.38) | SCN1ASCN2ASCN3ACHRM5CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3218333-B1 | FLUORIDE TRAPPING ARRANGEMENT | GE HEALTHCARE LTD (GB) | 2023-06-07 | — | — | EP | claimed |
| US-20150367005-A1 | METHOD OF SYNTHESIZING FLUORINE-18 LABELED RADIOPHARMACEUTICALS IN ETHANOL AND WATER | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2015-12-24 | — | — | US | claimed |
| US-20080171863-A1 | Method for Preparing of Organofluoro Compounds in Alcohol Solvents | FUTURECHEM CO., LTD. (KR) | 2008-07-17 | — | — | US | claimed |
| WO-2006082108-A2 | IMAGING METHOD AND COMPOSITION FOR IMAGING VASCULAR DISEASES | SCHERING AG (DE) | 2006-08-10 | — | — | WO | claimed |
| CN-118108800-A | Double-target probe of PSMA and GPC3, preparation method and application | 华中科技大学同济医学院附属同济医院 | 2024-05-31 | — | — | CN | disclosed |
| EP-3641772-B1 | TREATMENT OF HEPATOCELLULAR CARCINOMA CHARACTERIZED BY HEPATITIS B VIRUS INFECTION | CELGENE CORP (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-115692668-A | Carbon-coated positive electrode material and preparation method and application thereof | 格林美（无锡）能源材料有限公司 | 2023-02-03 | — | — | CN | disclosed |
| US-20220175770-A1 | TREATMENT OF HEPATOCELLULAR CARCINOMA CHARACTERIZED BY HEPATITIS B VIRUS INFECTION | CELGENE CORP (US) | 2022-06-09 | — | — | US | disclosed |
| CN-108699087-B | 18/19F labeled compounds targeting prostate specific membrane antigen | 不列颠哥伦比亚癌症局分支机构 | 2022-05-17 | — | — | CN | disclosed |
| EP-3765097-A1 | 2-ALKOXY-6-[18F]FLUORONICOTINOYL SUBSTITUTED LYS-C(O)-GLU DERIVATIVES AS EFFICIENT PROBES FOR IMAGING OF PSMA EXPRESSING TISSUES | Universität zu Köln (DE) | 2021-01-20 | — | — | EP | disclosed |
| US-10639608-B2 | System, device and method for preparing tracers and transferring materials during radiosynthesis | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2020-05-05 | — | — | US | disclosed |
| EP-3641772-A1 | TREATMENT OF HEPATOCELLULAR CARCINOMA CHARACTERIZED BY HEPATITIS B VIRUS INFECTION | Celgene Corporation (US) | 2020-04-29 | — | — | EP | disclosed |
| US-20080294289-A1 | Preparation and Use of Alkylating Agents | THE QUEEN'S MEDICAL CENTER (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080171863-A1 | Method for Preparing of Organofluoro Compounds in Alcohol Solvents | FUTURECHEM CO., LTD. (KR) | 2008-07-17 | — | — | US | disclosed |
| EP-1667794-A2 | SYSTEM AND METHOD FOR SYNTHESIS OF MOLECULAR IMAGING PROBES INCLUDING FDG | Molecular Technologies Inc. (US) | 2006-06-14 | — | — | EP | disclosed |
| EP-1660433-A2 | PREPARATION AND USE OF ALKYLATING AGENTS | The Queen's Medical Center (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20050123475-A1 | Preparation and use of alkylating agents | THE QUEEN'S MEDICAL CENTER | 2005-06-09 | — | — | US | disclosed |
| WO-2005009928-A2 | PREPARATION AND USE OF ALKYLATING AGENTS | THE QUEEN'S MEDICAL CENTER (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20040258615-A1 | System and method for synthesis of molecular imaging probes including FDG | MOLECULAR TECHNOLOGIES, INC. | 2004-12-23 | — | — | US | disclosed |
| WO-2004093652-A2 | SYSTEM AND METHOD FOR SYNTHESIS OF MOLECULAR IMAGING PROBES INCLUDING FDG | MOLECULAR TECHNOLOGIES, INC. (US) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171863-A1 | Method for Preparing of Organofluoro Compounds in Alcohol Solvents | ADH5, ADH1C, ADH1A | SCN1A 1668/4885SCN2A 2667/4885SCN3A 1433/4885 |
| US-20050123475-A1 | Preparation and use of alkylating agents | MGMT, MCL1, TOP2A | SCN1A 2479/4885SCN2A 2343/4885SCN3A 2214/4885 |
| US-20220175770-A1 | TREATMENT OF HEPATOCELLULAR CARCINOMA CHARACTERIZED BY HEPATITIS B VIRUS INFECTION | HAVCR2, HCCS, SLC10A1 | SCN1A 2616/4885SCN2A 3380/4885SCN3A 3060/4885 |
| US-20150367005-A1 | METHOD OF SYNTHESIZING FLUORINE-18 LABELED RADIOPHARMACEUTICALS IN ETHANOL AND WATER | TMEM14C, ADH1A, SELENOI | SCN1A 2187/4885SCN2A 2106/4885SCN3A 1519/4885 |
| US-10639608-B2 | System, device and method for preparing tracers and transferring materials during radiosynthesis | TERT, VHL, REV1 | SCN1A 4076/4885SCN2A 3926/4885SCN3A 4289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.